FIELD: biotechnology.
SUBSTANCE: there are presented: a glycosylated polypeptide containing an amino acid sequence, having at least 90 % identity to at least a fragment of von Willebrand factor (vWF), as well as use thereof to reduce the immune response to a second polypeptide, in particular a therapeutic protein, composition for treating or preventing a bleeding disorder in a patient, comprising a first and a second polypeptide in an effective amount, an isolated polynucleotide encoding a glycosylated polypeptide, a vector for producing a glycosylated polypeptide and a host cell.
EFFECT: novel molecule comprising an amino acid sequence having at least 90 % identity to at least a human von Willebrand factor (vWF) fragment, allows using it for effective treatment and prevention of blood clotting disorders in patient.
24 cl, 17 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
| ANTIBODIES AGAINST SIGLEC-15 AND THEIR APPLICATION METHODS | 2017 |
|
RU2759334C2 |
| ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| MUTATIONS IN OAS1 GENES | 2006 |
|
RU2465328C2 |
| ENGINEERED pH-DEPENDENT ANTI-CD3 ANTIBODIES, AS WELL AS METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832079C2 |
| METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND THEIR USE | 2015 |
|
RU2807602C2 |
